2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate 98%
| Price | Get Latest Price | |||
| Packge | 1kg | 5kg | 10kg | 25kg |
- Min. Order:10kg
- Time:2024-01-05
Product Details
- Product Name2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate
- EINECS No.603-873-1
- MFC23H19F2N3O6
- MW471.41
- AppearanceSolidOff-White
- Melting point 229-232°C
- storage temp. Sealed in dry,2-8°C
- Boiling point 608.4±65.0 °C(Predicted)
- density 1.45±0.1 g/cm3(Predicted)
Company Profile Introduction
AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds that produces autophagy-mediated cytotoxicity selectively in cancer cells.
The first drug candidate, ABTL0812, is currently in phase 2b clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a trial in endometrial cancer and squamous non-small cell lung cancer in Spain and France.
The phase 2a trial in endometrial cancer and lung cancer was conducted in Vall d’Hebron Institute of Oncology (VHIO, Barcelona), Institut Gustave Roussy (Paris), Centre Léon-Bérard (Lyon), Institut Català d’Oncologia (ICO, L'Hospitalet, Badalona and Girona), INCLIVA (Valencia), Institut Paoli-Calmettes (Marseille) and Hospital Universitario Virgen del Rocío (Sevilla)
Supplier other products
![3-[2-(3-Chloro-phenyl)-ethyl]-pyridine-2-carbonitrile](/ProductImageIndia/2024-03/Large/eca1f6ee-9f91-425e-86f7-d3751669b13e.png)
Recommended supplier
-
VIP1年
- Navone Specialties (OPC) Pvt Ltd
- 134790-39-9 99%
- Inquiry
- 2024-05-02
-
VIP1年
- Basil Drugs AND Pharmaceuticals Pvt Ltd
- 2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate 134790-39-9 98%
- Inquiry
- 2024-01-23
- Since:2020-01-01
- Address: Survey No. 285, KK Owners Association, IDA Doolapally, Jeedimetla, Hyderabad, Telangana-500 055, Ind